

Genital or Scalp Psoriasis: Risankizumab for Adult Subjects with Moderate to Severe Genital or Moderate to Severe Scalp Psoriasis

Genital or Scalp Psoriasis: Risankizumab for Adult Subjects with Moderate to Severe Genital or Moderate to Severe Scalp Psoriasis

The goal of this study is to evaluate the efficacy and safety of risankizumab for the treatment of moderate to severe genital psoriasis (Study-G) or moderate to severe scalp psoriasis (Study-S) in adults who are candidates for systemic therapy. The primary hypothesis is that risankizumab will provide superior efficacy compared to placebo. The study begins with a screening period to determine if subjects meet eligibility criteria. Those who are eligible will be randomized to receive subcutaneous doses of risankizumab or matching placebo. Depending on their response, subjects may be re-randomized during later stages of the study.

Basic eligibility criteria:

Please contact the study coordinator for additional eligibility information.

Researchderm@arizona.edu

Inclusion criteria:

- Subjects must be ≥ 18 years old
- Diagnosed with moderate to severe scalp psoriasis or moderate to severe genital psoriasis
- Do not have other concomitant inflammatory skin disorders.
- Able to comprehend and read the English language.

Primary disease category: [Dermatology](#)

Projected enrollment dates: April 2024

Official study title: Genital or Scalp Psoriasis: Risankizumab for Adult Subjects with Moderate to Severe Genital or Moderate to Severe Scalp Psoriasis